-
Denosumab for Bone Density Loss: Benefits vs. Risks
For some patients with degenerative bone disorders, the human monoclonal antibody denosumab can reduce BMD loss and the risk for fractures. Ongoing research is revealing the advantages and risks. Read more
-
Could a Multi-Cancer Early Detection Blood Test Signal a Seismic Shift for Cancer Screening?
Galleri, a test developed by California-based healthcare company Grail, can detect dozens of types of cancer — most of which currently lack a recommended screening test — with a single blood sample.... Read more
-
Exploring the Value of Patient Navigation
Patient navigation can benefit both patients maneuvering complex health systems and the health systems themselves, which often experience a high return on investment from navigation services. Read more
Deep Brain Stimulation at Some Frequencies May Be as Effective as Medication for Parkinson’s Disease
A new study offers hope for improving DBS treatments.
Denosumab for Bone Density Loss: Benefits vs. Risks
For some patients with degenerative bone disorders, the human monoclonal antibody denosumab can reduce BMD loss and the risk for fractures. Ongoing research is revealing the advantages and risks.
What’s New in Neurodegenerative Disease Research
In 2021, scientists continue to learn about diagnosis, treatment and prevention of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease.
Is the CAR T-Cell Revolution Here?
A tailor-made oncology treatment, CAR T-cell therapy promises to transform cancer care. But can its potential overcome its problems?
Could a Multi-Cancer Early Detection Blood Test Signal a Seismic Shift for Cancer Screening?
Galleri, a test developed by California-based healthcare company Grail, can detect dozens of types of cancer — most of which currently lack a recommended screening test — with a single blood sample. What could that mean for the way clinicians screen for and treat cancer?
- 1 of 249
- next ›